Adalat Oros: Uses, Dosage & Side Effects
A long-acting calcium channel blocker (dihydropyridine) for the treatment of high blood pressure and stable angina pectoris, delivering controlled 24-hour nifedipine release
Adalat Oros (nifedipine) is a long-acting calcium channel blocker used to treat high blood pressure (hypertension) and stable angina pectoris (chest pain from coronary heart disease). It belongs to the dihydropyridine class of calcium antagonists and works by relaxing the smooth muscle in blood vessel walls, which widens blood vessels, lowers blood pressure, and improves blood flow to the heart. The unique OROS (Osmotic-Release Oral System) technology delivers nifedipine at a controlled rate throughout the day, allowing convenient once-daily dosing with consistent 24-hour blood pressure control. Nifedipine is listed on the WHO Model List of Essential Medicines and remains one of the most widely prescribed antihypertensive agents worldwide.
Quick Facts: Adalat Oros
Key Takeaways
- Adalat Oros contains nifedipine, a dihydropyridine calcium channel blocker that relaxes blood vessel walls to lower blood pressure and improve coronary blood flow in angina pectoris.
- The OROS extended-release technology provides consistent 24-hour drug delivery with once-daily dosing, avoiding the blood pressure spikes and dips seen with immediate-release nifedipine formulations.
- Tablets must never be crushed, chewed, or split — doing so would destroy the controlled-release mechanism and could cause a dangerous rapid drop in blood pressure.
- Grapefruit juice must be avoided during treatment because it inhibits the CYP3A4 enzyme that metabolizes nifedipine, potentially causing excessive blood pressure lowering and increased side effects.
- Adalat Oros is contraindicated in early pregnancy (before week 20), during breastfeeding, in untreated heart failure, within the first 8 days after a heart attack, and in patients concurrently taking rifampicin.
What Is Adalat Oros and What Is It Used For?
Adalat Oros contains the active substance nifedipine, one of the most established and extensively studied calcium channel blockers in clinical medicine. Nifedipine belongs to the dihydropyridine subclass of calcium antagonists, a group of medications that selectively inhibit the influx of calcium ions through voltage-dependent L-type calcium channels in vascular smooth muscle and cardiac muscle cells. By blocking these channels, nifedipine reduces the intracellular calcium concentration required for muscle contraction, leading to relaxation of the smooth muscle lining blood vessel walls. This vasodilatory effect is the primary mechanism by which the drug lowers blood pressure and relieves angina symptoms.
High blood pressure (hypertension) occurs when the resistance to blood flow in the arteries is persistently elevated. Over time, uncontrolled hypertension damages blood vessels and significantly increases the risk of serious cardiovascular events including heart attack, stroke, heart failure, and kidney disease. The 2023 European Society of Hypertension (ESH) guidelines identify calcium channel blockers, including nifedipine, as one of the five major first-line antihypertensive drug classes alongside ACE inhibitors, angiotensin receptor blockers (ARBs), thiazide diuretics, and beta-blockers. By relaxing arterial smooth muscle, Adalat Oros reduces total peripheral vascular resistance and thereby lowers both systolic and diastolic blood pressure.
Stable angina pectoris is a clinical syndrome characterized by chest pain or discomfort that occurs when the heart muscle (myocardium) does not receive sufficient oxygen-rich blood, typically during physical exertion or emotional stress. The most common underlying cause is coronary artery disease, where atherosclerotic plaques narrow the coronary arteries. Adalat Oros benefits patients with stable angina through a dual mechanism: it reduces myocardial oxygen demand by decreasing the workload on the heart (through afterload reduction), and it improves myocardial oxygen supply by dilating coronary arteries and relieving coronary vasospasm. This combination makes nifedipine particularly effective for vasospastic (Prinzmetal) angina in addition to exertional angina.
What distinguishes Adalat Oros from earlier nifedipine formulations is its innovative drug delivery system. The OROS (Osmotic-Release Oral System) technology uses an osmotic pump mechanism to deliver nifedipine at a constant, controlled rate over a full 24-hour period. The tablet consists of an osmotically active drug core surrounded by a semipermeable membrane with a laser-drilled orifice. After ingestion, the tablet absorbs water through its semipermeable membrane, generating osmotic pressure that gradually pushes the dissolved drug through the tiny opening at a precisely controlled rate. This eliminates the rapid peak-and-trough plasma concentration fluctuations associated with immediate-release nifedipine capsules, which were historically linked to reflex tachycardia and other adverse cardiovascular effects.
The sustained and predictable drug delivery profile of Adalat Oros provides several important clinical advantages. First, it allows once-daily dosing, which simplifies treatment regimens and improves patient adherence. Second, the gradual onset of action avoids the reflex sympathetic activation (increased heart rate) that was problematic with short-acting nifedipine formulations. Third, the consistent 24-hour blood pressure control achieved with OROS technology covers the early morning hours, a period when cardiovascular events are most likely to occur. Clinical trials, including the landmark INSIGHT (Intervention as a Goal in Hypertension Treatment) study, have demonstrated that long-acting nifedipine GITS/OROS is as effective as co-amilozide (hydrochlorothiazide plus amiloride) in reducing cardiovascular morbidity and mortality in hypertensive patients.
After the drug has been released, the non-absorbable tablet shell is excreted intact in the stool. Patients may occasionally notice what appears to be a whole tablet in their feces. This “ghost tablet” is completely normal and does not mean the medication was not absorbed. The active drug has already been fully released and absorbed into the bloodstream by the time the empty shell passes through the gastrointestinal tract.
What Should You Know Before Taking Adalat Oros?
Before starting treatment with Adalat Oros, it is essential to discuss your complete medical history and all medications you are currently taking with your healthcare provider. Nifedipine, like all prescription medications, has specific contraindications and precautions that must be carefully considered to ensure the treatment is both safe and effective for your individual situation. The following sections outline the most important considerations.
Contraindications
There are several situations in which Adalat Oros must not be used. These absolute contraindications include:
- Allergy to nifedipine or excipients: Do not take Adalat Oros if you have a known allergy to nifedipine or any of the other ingredients in the tablet (see the “What Does Adalat Oros Contain?” section below).
- Early pregnancy (before week 20): Adalat Oros is contraindicated during the first 20 weeks of pregnancy due to potential risks to the developing fetus.
- Breastfeeding: Nifedipine passes into breast milk. Do not use Adalat Oros while breastfeeding unless specifically directed by your doctor.
- Untreated heart failure: Adalat Oros should not be used in patients with decompensated heart failure that is not adequately managed.
- Acute myocardial infarction: Do not use Adalat Oros during the first 8 days following a heart attack.
- Cardiovascular shock: The use of nifedipine is contraindicated in patients experiencing cardiovascular shock due to the risk of further blood pressure reduction.
- Concurrent rifampicin use: Rifampicin (used to treat tuberculosis) is a potent CYP3A4 enzyme inducer that dramatically reduces nifedipine blood levels, rendering the drug ineffective. These two medications must not be used together.
- Patients with an ileostomy after proctocolectomy (Kock pouch): The OROS delivery system requires normal gastrointestinal transit for proper drug release, which may be compromised in patients with a Kock pouch.
Warnings and Precautions
Certain medical conditions require careful evaluation and potentially closer monitoring when using Adalat Oros. Speak with your doctor before starting treatment if you have any of the following:
- Severe aortic stenosis: Narrowing of the aortic valve can limit the heart’s ability to compensate for the vasodilation caused by nifedipine, potentially leading to inadequate cardiac output and dangerous drops in blood pressure.
- Very low blood pressure (hypotension): Adalat Oros can further reduce blood pressure, which may be dangerous in patients who already have low baseline blood pressure readings.
- Impaired liver function: Nifedipine is extensively metabolized in the liver by CYP3A4 enzymes. Patients with liver disease may have reduced drug clearance, leading to higher-than-expected blood levels and increased risk of side effects. Dose adjustments may be necessary.
- Compensated heart failure: While nifedipine may be used cautiously in patients with stable, well-managed heart failure, careful monitoring is required because calcium channel blockers can theoretically worsen cardiac function.
- Gastrointestinal narrowing: Because the OROS tablet does not change shape or size as it passes through the digestive tract, patients with pre-existing significant narrowing of the gastrointestinal tract (strictures) should use caution. Obstruction symptoms have been reported rarely.
- Chronic inflammatory bowel disease: Patients with Crohn’s disease or ulcerative colitis should inform their doctor, as gastrointestinal conditions may affect drug absorption and tablet transit.
If you are scheduled for a radiological examination using contrast media, inform your healthcare team that you are taking Adalat Oros. The non-disintegrating tablet shell may appear as a filling defect on contrast imaging and could potentially be misinterpreted as a polyp.
Adalat Oros is not recommended for use in children and adolescents under 18 years of age. There is limited clinical data on the safety and efficacy of nifedipine extended-release tablets in pediatric populations. If blood pressure treatment is needed in children, alternative medications with established pediatric safety profiles should be considered.
Pregnancy and Breastfeeding
The use of Adalat Oros during pregnancy requires very careful consideration. During the first 20 weeks of pregnancy, the medication is strictly contraindicated. After week 20, nifedipine may be considered only when the potential benefit to the mother clearly outweighs the potential risk to the fetus, and only under the direct supervision of a physician experienced in managing hypertension in pregnancy. Women who are planning to become pregnant should discuss alternative antihypertensive options with their doctor well in advance.
Nifedipine is excreted into breast milk. Because the effects of nifedipine on the nursing infant have not been sufficiently studied, breastfeeding is generally not recommended during Adalat Oros treatment. If treatment with nifedipine is essential for the mother, the physician must weigh the benefits of breastfeeding against the potential exposure of the infant to the drug. In some cases, alternative antihypertensive medications that are more compatible with breastfeeding, such as labetalol, nifedipine immediate-release at low doses, or methyldopa, may be preferred.
Driving and Operating Machinery
Adalat Oros may cause side effects that can impair your ability to drive or operate machinery safely. Dizziness, headache, and fatigue are among the more common adverse reactions, and these are particularly likely at the beginning of treatment, after dose increases, or when switching from another antihypertensive medication. The combination of nifedipine with alcohol can further amplify these effects. Patients should assess their individual response to the medication before driving or engaging in activities requiring mental alertness.
Sodium Content
Each 30 mg Adalat Oros tablet contains approximately 9.4 mg of sodium. If the daily dose is increased to the maximum of 120 mg (four tablets), the total sodium intake from the medication rises to approximately 37.6 mg per day, which corresponds to about 1.88% of the WHO-recommended maximum daily sodium intake of 2 grams for adults. Patients on a strictly sodium-restricted diet should be aware of this contribution.
How Does Adalat Oros Interact with Other Drugs?
Nifedipine is primarily metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. Any drug or substance that significantly inhibits or induces CYP3A4 activity can alter nifedipine blood levels, potentially leading to either increased toxicity or reduced therapeutic efficacy. It is crucial that you inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medications, herbal products, and dietary supplements.
Major Interactions (Avoid Combination)
| Drug / Substance | Category | Effect on Nifedipine | Clinical Significance |
|---|---|---|---|
| Rifampicin | Anti-tuberculosis | Strongly decreases levels | Contraindicated. Rifampicin potently induces CYP3A4, reducing nifedipine to subtherapeutic levels |
| Grapefruit juice | Food/Beverage | Significantly increases levels | Avoid completely. Inhibits intestinal CYP3A4, causing excessive nifedipine absorption and hypotension |
| Ketoconazole, Itraconazole, Voriconazole, Posaconazole | Azole antifungals | Strongly increases levels | Potent CYP3A4 inhibitors. Risk of severe hypotension, edema, and other nifedipine toxicity |
| Ritonavir, Indinavir, Saquinavir, Atazanavir, Nelfinavir | HIV protease inhibitors | Strongly increases levels | Potent CYP3A4 inhibitors. Careful monitoring or alternative antihypertensive required |
Moderate Interactions (Use with Caution)
| Drug / Substance | Category | Effect on Nifedipine | Clinical Significance |
|---|---|---|---|
| Erythromycin, Clarithromycin, Telithromycin | Macrolide antibiotics | Increases levels | CYP3A4 inhibitors. Monitor blood pressure closely; dose reduction may be needed |
| Diltiazem | Calcium channel blocker | Increases levels | CYP3A4 inhibition. Additive blood pressure lowering and risk of excessive bradycardia |
| Verapamil | Calcium channel blocker | Increases levels | CYP3A4 inhibition. Risk of excessive hypotension, heart failure, and conduction abnormalities |
| Fluoxetine, Nefazodone | Antidepressants | Increases levels | CYP3A4 inhibition. Monitor for hypotension and edema |
| Cimetidine | H2-receptor antagonist | Increases levels | Inhibits hepatic metabolism. Blood pressure monitoring recommended |
| Phenytoin, Carbamazepine, Phenobarbital, Valproic acid | Antiepileptics | Decreases levels | CYP3A4 inducers. Nifedipine may become less effective; dose adjustment may be needed |
| St. John’s Wort | Herbal supplement | Decreases levels | CYP3A4 inducer. May reduce nifedipine efficacy significantly |
| Beta-blockers | Antihypertensives | Additive effect | Enhanced blood pressure lowering. Risk of worsening heart failure. Careful dose titration required |
| Digoxin | Cardiac glycoside | Nifedipine increases digoxin levels | Monitor digoxin levels and watch for signs of digoxin toxicity |
| Tacrolimus | Immunosuppressant | Nifedipine increases tacrolimus levels | Monitor tacrolimus blood levels closely; dose reduction may be required |
| Quinidine | Antiarrhythmic | Bidirectional interaction | Nifedipine may decrease quinidine levels. Monitor quinidine levels when starting or stopping nifedipine |
In addition to the interactions listed above, any other medication that lowers blood pressure — including other antihypertensives, nitrates, alpha-blockers, phosphodiesterase-5 inhibitors (such as sildenafil), and certain antidepressants — may have an additive blood pressure-lowering effect when combined with Adalat Oros. Your doctor will take all of these interactions into account when determining the appropriate dose and monitoring schedule.
Do not consume grapefruit or grapefruit juice at any time during treatment with Adalat Oros. Grapefruit contains compounds (furanocoumarins) that irreversibly inhibit intestinal CYP3A4 enzymes, which can dramatically increase the absorption and blood levels of nifedipine. This effect can persist for more than 24 hours after grapefruit consumption and may lead to dangerous hypotension, excessive flushing, headache, and peripheral edema.
What Is the Correct Dosage of Adalat Oros?
The dose of Adalat Oros is determined individually by your physician based on your condition, its severity, and your response to treatment. It is essential to follow your doctor’s dosing instructions precisely. Do not change your dose without medical guidance.
Adults
Hypertension (High Blood Pressure)
The recommended starting dose is 30 mg once daily. The usual maintenance dose is also 30 mg once daily. If blood pressure control is inadequate after an appropriate period (typically 2–4 weeks), your doctor may increase the dose to 60 mg once daily. In some patients, a maximum dose of 90 mg once daily may be considered, although this is less common.
Stable Angina Pectoris
The recommended starting dose is 30 mg once daily. Depending on the frequency and severity of anginal episodes, the dose may be increased to 60–90 mg once daily. Your doctor will carefully titrate the dose to achieve optimal symptom control while minimizing side effects.
Children and Adolescents
Under 18 Years
Adalat Oros is not recommended for children and adolescents under 18 years of age. There is insufficient clinical evidence on the safety and efficacy of nifedipine extended-release tablets in this age group. Pediatric patients requiring antihypertensive therapy should be managed with medications that have established pediatric dosing and safety data.
Elderly Patients
Over 65 Years
Elderly patients may be more sensitive to the effects of nifedipine and may have reduced hepatic metabolism. Treatment should generally begin at the lowest dose (30 mg once daily), and dose increases should be made cautiously with careful blood pressure monitoring. The extended-release formulation is preferred over immediate-release nifedipine in the elderly because it avoids rapid blood pressure fluctuations.
How to Take Adalat Oros
Adalat Oros tablets should be taken once daily, at approximately the same time each day, to maintain consistent blood levels. The tablets can be taken with or without food. Swallow each tablet whole with a glass of water or other suitable liquid. Do not crush, chew, or break the tablets, as this would destroy the osmotic-release mechanism and could result in the entire dose being released at once, potentially causing a dangerous drop in blood pressure.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a forgotten one. If you frequently forget doses, consider using a pill organizer or setting a daily alarm as a reminder.
Overdose
If you have taken more Adalat Oros than prescribed, or if someone else (especially a child) has accidentally ingested the medication, seek immediate medical attention by contacting your local emergency services or poison control center. Symptoms of nifedipine overdose may include severe hypotension (dangerously low blood pressure), rapid or irregular heartbeat, dizziness, fainting, nausea, and in severe cases, loss of consciousness. The extended-release nature of the tablet means that symptoms may be delayed and prolonged, requiring extended medical observation even if the patient initially appears well.
What Are the Side Effects of Adalat Oros?
Like all medications, Adalat Oros can cause side effects, although not everyone experiences them. Most side effects are a direct consequence of the drug’s vasodilatory mechanism and tend to occur early in the course of treatment. They often become less troublesome as the body adapts to the medication over the first few weeks. If side effects are severe, persistent, or worrying, consult your healthcare provider. Do not stop taking Adalat Oros without medical advice, as abruptly discontinuing antihypertensive medication can cause a rebound increase in blood pressure.
Stop taking Adalat Oros and contact a doctor immediately if you experience signs of angioedema: swelling of the face, tongue, or throat; difficulty swallowing; hives; or breathing difficulties. Angioedema is classified as an uncommon side effect (affecting fewer than 1 in 100 people).
Adalat Oros can, in rare cases, affect white blood cells, leading to impaired immune defenses. If you develop an infection with symptoms such as fever with severely deteriorated general condition, or fever with localized infection symptoms (such as severe sore throat or urinary difficulties), contact your doctor promptly so a blood test can be performed to rule out agranulocytosis (dangerously low white blood cell count).
Common
Affects more than 1 in 100 people
- Peripheral edema (swelling, especially of the ankles and feet)
- Headache
- Facial flushing with sensation of warmth
- Constipation
- General malaise (feeling unwell)
Uncommon
Affects fewer than 1 in 100 people
- Allergic reactions and angioedema
- Anxiety reactions and sleep disturbances
- Dizziness, migraine, and tremor
- Visual disturbances
- Increased heart rate (tachycardia) and palpitations
- Low blood pressure (hypotension) and fainting
- Nosebleeds and nasal congestion
- Abdominal pain, nausea, indigestion, and flatulence
- Dry mouth
- Transient elevation of liver enzymes
- Skin redness (erythema)
- Muscle cramps and joint swelling
- Increased urinary frequency and urinary difficulties
- Erectile dysfunction
- Non-specific pain and chills
Rare
Affects fewer than 1 in 1,000 people
- Pruritus (itching)
- Urticaria (hives) and skin rash
- Paraesthesia (tingling or abnormal skin sensations)
- Gingival hyperplasia (overgrowth of gum tissue)
Not Known
Frequency cannot be estimated from available data
- Severe anaphylactic/anaphylactoid reactions
- Hyperglycemia (elevated blood sugar)
- Numbness, drowsiness, and eye pain
- Chest pain (angina pectoris) and shortness of breath
- Bezoars (masses of non-digestible tablet shells in the stomach)
- Difficulty swallowing, intestinal obstruction, and intestinal ulcers
- Vomiting and gastroesophageal reflux (heartburn)
- Jaundice and severe skin reactions (toxic epidermal necrolysis)
- Photosensitivity reactions and purpura (reddish-purple skin spots)
- Joint and muscle pain
The extended-release formulation of Adalat Oros generally produces fewer and milder side effects compared with immediate-release nifedipine capsules. This is because the OROS system avoids the rapid peak plasma concentrations that are more likely to trigger vasodilatory side effects such as flushing, headache, and reflex tachycardia. Nonetheless, individual responses vary, and patients starting treatment should be aware that side effects are most common during the first few days to weeks of therapy.
It is important to report any suspected side effects after a medicine has been authorized. This allows continuous monitoring of the medicine’s benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance agency (e.g., the FDA MedWatch program in the US, the Yellow Card Scheme in the UK, or the relevant authority in your country).
How Should You Store Adalat Oros?
Proper storage of Adalat Oros is essential to maintain the medication’s stability and effectiveness. Nifedipine is sensitive to light and moisture, which is why the tablets are packaged in protective blister packs. Follow these storage guidelines:
- Original packaging: Always store the tablets in the original blister packaging. Do not remove tablets from the blister until you are ready to take them.
- Moisture protection: Adalat Oros is moisture-sensitive. Keep the blister packs tightly sealed in a dry environment. Do not store in the bathroom or other humid areas.
- Temperature: Store at room temperature (typically below 25°C / 77°F). Avoid exposure to excessive heat or direct sunlight.
- Expiry date: Check the expiry date printed on the packaging. Do not use Adalat Oros after the stated expiry date.
- Child safety: Keep this medication out of the sight and reach of children. Consider using a child-proof storage location.
- Disposal: Do not flush medications down the toilet or pour them into drains. Return unused or expired medications to a pharmacy or follow local guidelines for safe medication disposal to protect the environment.
What Does Adalat Oros Contain?
Understanding what your medication contains is important for identifying potential allergens and understanding the pharmaceutical design of the product. Adalat Oros tablets contain the following components:
Active Ingredient
Each tablet contains 30 mg of nifedipine, a dihydropyridine calcium channel blocker that is the pharmacologically active component responsible for the blood pressure-lowering and anti-anginal effects of the medication.
Inactive Ingredients (Excipients)
The following excipients serve various functions in the OROS delivery system and tablet formulation:
- Iron oxide — Colorant (gives the tablet its characteristic pink appearance)
- Magnesium stearate — Lubricant for the manufacturing process
- Sodium chloride — Osmotic agent (creates the osmotic pressure that drives drug release)
- Hypromellose (HPMC) — Polymer used in the drug core and coating
- Cellulose acetate — Forms the semipermeable membrane coating
- Polyethylene glycol (PEG) — Plasticizer and solubilizer
- Polyethylene oxide — Osmotic push layer component
- Hydroxypropyl cellulose — Binder and film-forming agent
- Titanium dioxide — Opacifier and UV protectant in the coating
- Propylene glycol — Solvent used in the coating process
Appearance and Packaging
Adalat Oros 30 mg tablets are round, convex, pink extended-release tablets with a laser-drilled hole on one side, marked with “Adalat 30”. They are available in blister packs of 28 and 98 tablets, as well as unit-dose packs of 49 tablets (49×1). Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Adalat Oros
Adalat Oros (nifedipine extended-release) is a calcium channel blocker used to treat two main conditions: high blood pressure (hypertension) and stable angina pectoris (chest pain caused by reduced blood flow to the heart). It works by relaxing the smooth muscle in blood vessel walls, which widens blood vessels, lowers blood pressure, and improves blood and oxygen supply to the heart muscle. The extended-release OROS formulation provides consistent 24-hour blood pressure control with once-daily dosing.
No, you should not drink grapefruit juice while taking Adalat Oros. Grapefruit juice inhibits the CYP3A4 enzyme that metabolizes nifedipine, which can significantly increase the drug’s blood levels and amplify its effects and side effects. This interaction can lead to excessive blood pressure lowering, dizziness, flushing, and increased heart rate. The effect of grapefruit can persist for more than 24 hours, so it should be avoided entirely during treatment. Other citrus fruits such as oranges are generally safe.
No, Adalat Oros tablets must never be crushed, chewed, or split. The tablets use a sophisticated osmotic-release oral system (OROS) that delivers nifedipine at a controlled rate over 24 hours. Crushing or breaking the tablet would destroy this controlled-release mechanism and could release the entire dose at once, potentially causing a dangerous and rapid drop in blood pressure. If you have difficulty swallowing tablets, talk to your doctor about alternative nifedipine formulations or other suitable medications.
Adalat Oros must not be used during the first 20 weeks of pregnancy. After week 20, nifedipine may be used only under strict medical supervision when the benefit to the mother clearly outweighs any potential risk to the fetus. Women who are planning pregnancy should discuss alternative antihypertensive medications with their doctor well in advance. Nifedipine passes into breast milk, so breastfeeding while taking Adalat Oros is generally not recommended unless a physician determines the benefits outweigh the risks.
Adalat Oros begins lowering blood pressure within a few hours of the first dose, with peak plasma concentrations reached approximately 6–12 hours after administration. However, the full therapeutic benefit of consistent blood pressure control may take several days to weeks of regular daily dosing. Unlike immediate-release nifedipine, the OROS formulation is designed for gradual onset, which avoids the rapid blood pressure drops and reflex tachycardia associated with short-acting preparations.
This is completely normal and is not a cause for concern. Adalat Oros uses an osmotic pump system enclosed in a non-absorbable tablet shell. After the active drug has been fully released and absorbed into your bloodstream during its passage through the gastrointestinal tract, the empty shell continues through the digestive system and is excreted intact. This “ghost tablet” does not contain any remaining medication and its presence in the stool does not mean the drug was not properly absorbed.
References
- European Medicines Agency (EMA). Adalat Oros — Summary of Product Characteristics (SmPC). Last updated 2024.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874–2071.
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). The Lancet. 2000;356(9227):366–372.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. 2023.
- British National Formulary (BNF). Nifedipine. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management (NICE guideline NG136). Updated 2023.
- Toal CB, Mahon WA, et al. Nifedipine gastrointestinal therapeutic system (GITS): bioavailability and pharmacokinetic comparison with the OROS formulation. Journal of Cardiovascular Pharmacology. 1996;27(3):399–405.
- Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial). The Lancet. 2004;364(9437):849–857.
- European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–477.
Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Cardiology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent expert panel following ESH, ESC, and WHO guidelines
Evidence Standard
Level 1A — Based on systematic reviews, meta-analyses, and randomized controlled trials
Accessibility
WCAG 2.2 Level AAA — Optimized for screen readers, keyboard navigation, and assistive technologies
Last reviewed: | Published:
Editorial policy: All content is independently created and reviewed. iMedic receives no commercial funding and has no pharmaceutical industry affiliations. For more information, see our editorial standards.